Fueling Innovation: Aeon Advanced Invests $12M in bioAffinity Technologies to Revolutionize Early Lung Cancer Diagnosis

bioAffinity Technologies, Inc. is thrilled to announce that it has raised $12,000,000 in a recent funding round, marking a pivotal milestone in its mission to transform early-stage lung cancer diagnosis. This significant capital infusion comes from Aeon Advanced Deterrence Technologies, underscoring their confidence in bioAffinity’s revolutionary approach to noninvasive disease detection and their commitment to advancing healthcare innovation. The company’s flagship product, CyPath® Lung, is a groundbreaking flow cytometry-based test that has demonstrated exceptional sensitivity, specificity, and accuracy in detecting early-stage lung cancer. By focusing on the identification of pulmonary nodules—often the first hint of potential malignancy—CyPath® Lung promises to enhance diagnostic precision, boost patient survival rates, and reduce the need for invasive procedures. The newly raised funds will primarily support the continued development and broader commercialization of CyPath® Lung as a Laboratory Developed Test, currently licensed by Precision Pathology Services for further refinement and market rollout. This strategic investment will enable bioAffinity Technologies to scale its research initiatives, optimize manufacturing processes, and expand clinical trials, ultimately aiming to integrate this cutting-edge diagnostic tool into routine clinical practice. Moreover, the funding will empower the company to explore additional applications of its innovative flow cytometry technology for other lung diseases, further cementing its position as a leader in early disease detection. With a focus on improving patient outcomes and reducing healthcare costs, bioAffinity Technologies is poised to make a lasting impact on the diagnostic landscape, offering a beacon of hope for patients and clinicians alike.